Search results for "Infusions"

showing 10 items of 168 documents

Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass

1993

In a 3-week-old male newborn persistent suprasystemic pulmonary hypertension developed after surgical valvulotomy for a critical aortic valve stenosis. Because of a residual transvalvular pressure gradient of 35 mmHg and postoperative left as well as right ventricular dysfunction, treatment with inhaled nitric oxide (NO) and intravenously infused prostacyclin (PGI2) was attempted. Low-dose inhaled NO and low dose PGI2 corrected severe pulmonary hypertension and led to an increase in cardiac output. Treatment with NO but not PGI2 was accompanied by a rise in PaO2 and systemic blood pressure. Interruption of NO administration led to a rapid increase in pulmonary arterial pressure to suprasyst…

Malemedicine.medical_specialtyCardiac outputHypertension Pulmonarymedicine.medical_treatmentBlood PressureNitric OxidePostoperative ComplicationsInternal medicineHypoxic pulmonary vasoconstrictionAdministration InhalationmedicineHumansEndothelial dysfunctionInfusions IntravenousPulmonary wedge pressureCardiopulmonary Bypassbusiness.industryHemodynamicsInfant NewbornAortic Valve Stenosismedicine.diseaseEpoprostenolPulmonary hypertensionValvulotomyBlood pressureAnesthesiaAortic valve stenosisPediatrics Perinatology and Child Healthcardiovascular systemCardiologyDrug Therapy CombinationbusinessEuropean Journal of Pediatrics
researchProduct

Novel antihypertensive hexa- and heptapeptides with ACE-inhibiting properties: From the in vitro ACE assay to the spontaneously hypertensive rat

2011

Bioactive ACE inhibiting peptides are gaining interest in hypertension treatment. We have designed and screened six synthetic heptapeptides (PACEI48 to PACEI53) based on two hexapeptide leads (PACEI32 and PACEI34) to improve ACE inhibitory properties and assess their antihypertensive effects. ACE activity was assayed in vitro and ex vivo. Selected peptides were administered to spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats. In vitro cytotoxicity was assessed with the MTT reduction test. The six heptapeptides at low micromolar concentration produced different degrees of in vitro inhibition of ACE activity using the synthetic substrate HHL or the natural subst…

Malemedicine.medical_specialtyCell SurvivalPhysiologyAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressurePeptidyl-Dipeptidase APharmacologyRats Inbred WKYBiochemistryTissue Culture TechniquesMiceCellular and Molecular NeuroscienceEndocrinologySpontaneously hypertensive ratOral administrationRats Inbred SHRInternal medicineRenin–angiotensin systemmedicineAnimalsHumansInfusions IntravenousAntihypertensive AgentsbiologyChemistryAngiotensin-converting enzyme3T3 CellsHep G2 CellsIn vitroRatsCarotid ArteriesEndocrinologyVasoconstrictionHypertensionACE inhibitorbiology.proteinRabbitsAngiotensin Imedicine.symptomOligopeptidesVasoconstrictionEx vivomedicine.drug
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refr…

2000

Background: Diuretics, have been accepted as first-line treatment in refractory heart failure, but a lack of response is a frequent event. A randomised single blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory NYHA class IV congestive heart failure (CHF). Materials and methods: Sixty patients (21 F/39 M) with refractory CHF (NYHA class IV) of different etiologies, unresponsive to high oral doses of furosemide, ACE-inhibitors, digitalis, and nitrates, aged 65–90 years, were enrolled. They had to have an ejection fraction (EF) < 35%, serum creatinine < 2 mg/dl, B…

Malemedicine.medical_specialtyDiuresisBlood PressurePotassium Chloridechemistry.chemical_compoundBolus (medicine)FurosemideHeart RateHumansMedicineSingle-Blind MethodDiureticsInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicCreatinineEjection fractionbusiness.industryBody WeightSodiumFurosemideMiddle Agedmedicine.diseaseHypokalemiaDiuresisUric AcidSurgerychemistryCreatinineAnesthesiaHeart failurePotassiumDrug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugEuropean Journal of Heart Failure
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Fabry disease: enzyme replacement therapy

2003

Fabry disease is a multisystem disorder associated with wide variability in clinical expression. Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A. The enzyme defect leads to the systemic accumulation of glycosphingolipids with alpha-galactosyl moieties consisting predominantly of globotriaosylceramide, galabiosylceramide and two additional glycosphingolipids. Four hemizygotes patients with a family history of Fabry disease and deficiency of the enzyme alpha-galactosidase A were selected. Each patient received purified alpha-galactosidase by intravenous infusion (0.2 mg/kg). The infusion was administered every 2 weeks, for 40 min, for a …

Malemedicine.medical_specialtyGlobotriaosylceramideRenal functionVasomotionCorneal dystrophyDermatologyRisk AssessmentGastroenterologyDrug Administration ScheduleSampling Studieschemistry.chemical_compoundInternal medicineHumansMedicineFamily historyInfusions IntravenousDose-Response Relationship Drugbusiness.industryBiopsy NeedleOutcome measuresEnzyme replacement therapymedicine.diseaseImmunohistochemistryFabry diseaseTreatment OutcomeInfectious DiseasesEndocrinologychemistryalpha-GalactosidaseFabry DiseaseFemalebusinessFollow-Up StudiesJournal of the European Academy of Dermatology and Venereology
researchProduct

Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compe…

2011

INTRODUCTION: Hypertonic saline solution (HSS) and a moderate Na restriction plus high furosemide dose showed beneficial effects in compensated heart failure (HF), in short and long terms. The study was aimed to verify the effects of this combination on hospitalization time, readmissions and mortality in patients in New York Heart Association (NYHA) class III. METHOD: Chronic ischemic or nonischemic cardiomyopathy uncompensated patients with HF in NYHA III functional class with ejection fraction <40%, serum creatinine <2.5 mg/dL, blood urea nitrogen <60 mg/dL and reduced urinary volume were single-blind randomized in 2 groups: the first group received a 30-minute intravenous infusion of fur…

Malemedicine.medical_specialtyHeart diseasemedicine.medical_treatmentDiuresisPatient ReadmissionFurosemideInternal medicinemedicineHumansInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionbusiness.industrySodiumFurosemideGeneral MedicineDiet Sodium-RestrictedMiddle Agedmedicine.diseaseHyepertonic saline heart failure diureticsDiuresisSurgeryHospitalizationTreatment OutcomeHeart failureCirculatory systemCardiologyTonicityFemaleDiureticbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Hypertonic saline solution and decompressive craniectomy for treatment of intracranial hypertension in pediatric severe traumatic brain injury.

2002

Experimental data 8 –11 and first clinical results in adults 12,13 suggest that hypertonic saline ( 1.0) may be highly effective in lowering ICP even when mannitol has lost its therapeutic potential after prolonged and repeated use. In children, only limited experience exists with the use of hypertonic saline solutions: a randomized prospective study in children with severe head injury compared the effects on ICP (increased to 15–20 mm Hg) of isotonic (0.9% NaCl) and hypertonic (3% NaCl) saline injections, demonstrating a beneficial effect of the hypertonic solution. 14 Another prospective randomized trial compared the effects of continuous infusion of either lactated Ringer’s solution (277…

Malemedicine.medical_specialtyIntracranial PressureTraumatic brain injurymedicine.medical_treatmentBrain damageCritical Care and Intensive Care MedicineDrug Administration ScheduleInjury Severity ScorePreoperative CaremedicineHumansChildInfusions IntravenousSalineOsmolePostoperative CareSaline Solution Hypertonicbusiness.industryHead injurySodiumGlasgow Coma ScaleAccidents Trafficmedicine.diseaseDecompression SurgicalHypertonic salineSurgeryAnesthesiaBrain InjuriesSurgeryDecompressive craniectomyAccidental Fallsmedicine.symptomIntracranial HypertensionbusinessTomography X-Ray ComputedCraniotomyThe Journal of trauma
researchProduct

Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone Dur…

2003

The purpose of this study was to evaluate if the variations of heart magnetic resonance imaging in beta-thalassemia major patients treated with Deferoxamine B mesylate (DF) or Deferiprone (L1) chelation therapy is a useful tool of the indirect myocardial iron content determination. For this reason, a prospective study was carried out. Seventy-two consecutive patients with beta-thalassemia major (35 treated with DF and 37 with L1) were studied. The main outcome results were laboratory parameters including determination of the liver iron concentration (LIC) and magnetic resonance imaging (MRI) of the heart and liver. The heart to muscle signal intensity ratios (HSIRs) were significantly incre…

Malemedicine.medical_specialtyLiver Iron ConcentrationPyridonesIronThalassemiaClinical BiochemistryAdministration OralDeferoxamineIron Chelating AgentsGastroenterologychemistry.chemical_compoundInternal medicinemedicineHumansDeferiproneInfusions ParenteralChelation therapyProspective cohort studyGenetics (clinical)medicine.diagnostic_testbusiness.industryMyocardiumbeta-ThalassemiaBiochemistry (medical)Beta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseMagnetic Resonance ImagingDeferoxaminechemistryHeart Function TestsPatient ComplianceFemalebusinessDeferipronemedicine.drugHemoglobin
researchProduct

Hepatic extraction of isosorbide dinitrate in cardiac patients

1983

Hepatic extraction of organic nitrates, including that of isosorbide dinitrate (ISDN), has been thought to be nearly complete in man but has never been directly measured. We examined the time course of plasma ISDN and metabolite concentrations in arterial and hepatic venous blood in four cardiac patients receiving an intravenous ISDN infusion. Apparent hepatic extraction of ISDN was high (90%) at the beginning of infusion but fell to about 44% 1 hr after termination of infusion. The decrease in ISDN concentration gradient across the liver correlates with an increase in plasma isosorbide-5-mononitrate concentration, but a cause-and-effect relationship resulting from metabolite inhibition can…

Malemedicine.medical_specialtyMetaboliteBiological AvailabilityCoronary DiseaseIsosorbide DinitratePharmacologylaw.inventionchemistry.chemical_compoundlawInternal medicineHepatic extractionmedicineHumansInfusions ParenteralPharmacology (medical)In patientPharmacologyClinical pharmacologybusiness.industryVenous bloodMiddle AgedBioavailabilityKineticsEndocrinologyLiverchemistryTime courseIsosorbide dinitratebusinessmedicine.drugClinical Pharmacology and Therapeutics
researchProduct

Increased plasma concentration of fibrin monomer in acute myocardial infarction with early reperfusion.

1996

OBJECTIVE To assess whether plasma fibrin monomer (FM) concentration, a marker of thrombin activity, is increased in the first hours after acute coronary occlusion and whether there are differences between patients with and without early reperfusion. DESIGN Thirty-five consecutive patients with acute myocardial infarction (AMI) and early coronary angiography were studied prospectively. METHODS Plasma FM samples taken on admission (< 6 h after onset of chest pain) and 6-14 h after onset of chest pain were analysed using a specific enzyme immunoassay. All of the patients were anticoagulated with heparin intravenously. RESULTS Of the 35 patients, 28 had angiographically documented reperfusion …

Malemedicine.medical_specialtyMyocardial InfarctionReference rangeMyocardial ReperfusionChest painCoronary AngiographySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsImmunoenzyme TechniquesTroponin TInternal medicinemedicineHumansMyocardial infarctionProspective StudiesInfusions IntravenousCreatine KinasebiologyTroponin Tbusiness.industryHeparinAnticoagulantsGeneral MedicineHeparinMiddle Agedmedicine.diseaseFibrin MonomerTroponinCoronary occlusionbiology.proteinCardiologyCreatine kinaseFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugCoronary artery disease
researchProduct